A report in the April 2007 issue of Psychiatric Services has identified a unique subgroup of schizophrenia patients in the United States who tend to receive depot antipsychotic medications.
There is no evidence that antioxidant supplements interfere with the therapeutic effects of chemotherapy agents, according to a recent systematic review of the use of antioxidants during chemotherapy, available in the May, 2007 issue of the peer-reviewed journal Cancer Treatment Reviews.
The National institute on Drug Abuse (NIDA), part of the National Institutes of Health, will present a full day symposium on the epidemiology of stimulant abuse and treatment as part of the 38th Annual Medical-Scientific Conference of the American Society of Addiction Medicine (ASAM).
More than 900 scientists, parents and activists from around the world who are focused on understanding the causes of autism and finding treatments for the developmental disorder will gather in Seattle May 3-5 to share the latest research findings at the sixth annual International Meeting for Autism Research.
An incontinent prisoner forced to use a bin bag to protect his mattress. A diabetic who regularly misses breakfast because only high sugar cereals are on offer. Just two of the anecdotes to emerge from in-depth interviews with prisoners. UK study also includes comments on health issues in prisons worldwide.
Yerkes researchers will compare aging nonhuman primates to aging humans in an effort to develop more effective treatment options for aging-related diseases.
A simple modification in an anti-cancer treatment currently in clinical trials substantially improves the drug?s effectiveness and reduces side effects in experiments with laboratory mice, researchers are reporting in an article scheduled for the May 16 edition of ACS? Bioconjugate Chemistry, a bi-monthly journal.
A new study published in PLoS Medicine suggests that so-called “detail” visits to doctors made by drug company representatives can involve promotion of drugs for non-approved, “off-label” uses.
Wan, et al evaluated 95 infants who presented with a urinary tract infection. They reviewed the clinical and laboratory findings as well as the diagnosis and treatment.
The anti-anginal medication ranolazine was shown to be safe in regard to certain outcomes but did not reduce the risk of major cardiovascular events such as death, heart attack or recurrent ischemia following acute coronary syndromes, according to a study in the April 25 issue of JAMA.